I believe there is. It's called ETHANOL.Anyone know of a drug with strongish GABAergic, NMDA Antagonistic, and Mild Anti-Cholinergic properties? Now that would be one hell of a sedative.

N&PD Moderators: Skorpio | someguyontheinternet
I believe there is. It's called ETHANOL.Anyone know of a drug with strongish GABAergic, NMDA Antagonistic, and Mild Anti-Cholinergic properties? Now that would be one hell of a sedative.
The 2 major types of membrane-bound proteins that are directly affected by pharmacologically relevant concentrations of ethanol (i.e., concentrations up to 100 mmol/L or 460 mg/dL, at which point ethanol can be lethal in humans) are ligand-gated ion channels (LGICs) and voltage-dependent calcium channels. LGICs are a family of neurotransmitter receptors that are widely distributed in the mammalian CNS and play a major role in synaptic transmission and the regulation of neuronal excitability. In particular, the gamma-aminobutyric acid type A (GABAA), N-methyl-D-aspartate (NMDA), glycine, neuronal nicotinic and 5-hydroxytryptamine type 3 (5-HT3) receptors are LGICs that have been shown to be directly modulated by ethanol. Ethanol does not modulate these receptors in a non-specific fashion; interestingly, it potentiates ligand-gated currents at some receptors but inhibits them at others. For example, it is well documented that acute ethanol exposure potentiates these currents at GABAA and glycine receptors but inhibits them at NMDA receptors. Voltage-gated calcium channels play key roles in neurotransmitter release, hormone secretion, gene regulation and differentiation. Ethanol, when administered acutely, has been shown to block voltage-gated calcium channels at pharmacologically relevant concentrations.
Which sedative is better: GABA action or Antihistamine?
Sedative and anticonvulsant effects of adenosine analogs in mouse and rat.
Abstract
The behavioral and physiological effects of L-phenylisopropyladenosine, cyclohexyladenosine and 2-chloroadenosine were examined in mice and rats. These analogs of adenosine are agonists which bind with high affinity to putative central A1 receptors in vitro. Relatively low doses of these drugs administered i.p. produced marked sedation and hypothermia; higher doses resulted in an almost complete cessation of spontaneous motor activity as well as some ataxia. These analogs also antagonized seizures elicited by a variety of convulsants with different mechanisms of action. The differences observed in the anticonvulsant potencies of the analogs suggest that these effects are not produced by the interaction of these drugs with a single class of adenosine receptor. In particular, 2-chloroadenosine and cyclohexyladenosine appear to be more related to each other pharmacologically than to L-phenylisopropyladenosine. Because some of the anticonvulsant actions of L-phenylisopropyladenosine are not reversed by the adenosine antagonist theophylline, and are not shared by the other analogs, these may reflect actions mediated by other, perhaps nonpurinergic receptors. Although benzodiazepines also have sedative, hypothermic and anticonvulsant properties, responses to benzodiazepines can be clearly dissociated from responses to the adenosine agonists.
Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake
Abstract
Adenosine A(2A) receptors are involved in the regulation of several behavioral functions. Adenosine A(2A) antagonists exert antiparkinsonian effects in animal models, and adenosine A(2A) agonists suppress locomotion and impair various aspects of motor control. The present experiments were conducted to study the effects of low doses of the adenosine A(2A) agonist CGS 21680 on lever pressing, specific parameters of food intake, and sedation. In the first experiment, the effects of CGS 21680 on fixed ratio 5 lever pressing were assessed. In the second experiment, rats were tested in 30 min feeding sessions, and also were observed for drug-induced sedation using a sedation rating scale. CGS 21680 (0.025, 0.05, 0.1 mg/kg IP) produced a dose related suppression of lever pressing, and also reduced the amount of food consumed. The feeding effect was largely dependent upon a slowing of the rate of feeding, and there was only a modest suppression of time spent feeding. Doses of CGS 21680 that suppressed lever pressing and feeding also were associated with sedation/drowsiness. In conjunction with other studies, the present results suggest that sedative effects may play an important role in some of the behavioral effects produced by systemic administration of adenosine A(2A) agonists.
Taken together, these data suggest that the new orally bioavailable neuroactive steroid CCD-3693 has NREM-promoting potency comparable to the endogenous neuroactive steroid, pregnanolone. Although CCD-3693 potentiates alcohol comparable to benzodiazepine receptor ligands, some notable potential advantages over triazolam and zolpidem were observed: CCD-3693 appeared to be more intrinsically potent in promoting NREM sleep. The neuroactive steroids did not interfere significantly with REM sleep and selectively reduced EEG wakefulness without disproportionate locomotor activity inhibition. In addition, the benzodiazepines ligands showed distinct “rebound” wakefulness after the NREM-promoting effect subsided, although the neuroactive steroids did not.
Because neuroactive steroids are naturally synthesized in the brain by enzymes in situ (Baulieu, 1981) and potently facilitate GABA-dependent chloride flux (Gee et al., 1988), it is plausible that these compounds are endogenous physiological regulators of brain excitability with diffuse action throughout the CNS. Neurotransmitters such as adenosine have similar diffuse inhibitory action and, on that basis, are postulated to be involved in normal sleep regulation (Benington and Heller, 1995). In this sense, the efficacy and therapeutic application of CCD-3693 as a sedative hypnotic could also constitute a pharmacological modification of a natural sleep-promoting physiological mechanism.
Qetiapine is soo nasty!
I remember taking the prolong form as a sleep aid and, I can tell you I was totally useless the following day for even the simplest tasks.
Antipsychotic brain nailer at its best. Maybe the problem was the prolong formulation that carried blood levels to the next day.
What I wanted to contribute to this thread is Erythrina vera or Mulungu.
Since Kratom is the Herbal OTC opioid , this would equal the herbal OTC Benzodiazepine.
25-30g of bark brewed as a tea produce very noticeable effects which totally remind me on benzos. Even the afterglow feels like a benzo hangover. Does anyone have some deeper insight on its active compounds?
Since it is totally available and definitely active it should be mentioned here.
sounds like your asking a bit much there - longterm antihistamine/acetylcholine mediated sedation, norepinephrine stimulation to aid wakefullness upon waking up as well as choline modulation.
You could get combinations to do what you're after there but getting that all bound up into one pill seems a bit much.
I haven't spent too much time trying different anticholinergenic meds in terms of sedation, but as far as antihistamines go I don't see how they are much better than GABA based sedatives in terms of tolerance / addiction; edit - I guess what I mean is you can end up addicted to both but imo gabas work better; sure withdrawing from benzos is far worse than withdrawing from diphenhydramine, but either way you end up with rebound insomnia
DPH had a huge tolerance problem, that's news to me.
Anti-histamines have a much shallower tolerance curve and much milder withdrawal than GABAnergics; Mgrady is fundamentally mistaken.
ebola